Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MinervaX’s Develops GBS vaccine for Senior Citizens

MinervaX’s Develops GBS vaccine for Senior Citizens

4th July 2023

The experiment is being conducted at the Centre for Vaccinology. Although the majority of Guillain-Barre syndrome (GBS) instances are associated with expectant mothers and infants, severe GBS infections within the senior citizens are emerging.

Those with additional medical problems including diabetes, cancer or a weakened immune system are more vulnerable to developing adverse effects.
MinervaX has now broadened the research and development pathway for its innovative GBS vaccine to cover older persons. They did this in order to avoid and minimise worldwide GBS-related fatalities.

Two vaccinations studies are being conducted by MinervaX to prevent fatal diseases in infants. The research studies indicate that the vaccine has an acceptable safety record, promotes an immune reaction, and stimulates the development of biologically active antigens.

Dr Isabel, Leroux-Roels, CEVAC’S chief investigator announced “We at CEVAC are very thrilled to be participating to this phase 1 trial against this serious disease. To show that MinervaX’s innovative vaccine is effective, it is a step forward to find the numerous volunteers for this very crucial experiment”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.